earnings
confidence high
sentiment neutral
materiality 0.70
Organon Q3 revenue $1.6B (-1% YoY); adj. EPS $1.67; FY guidance narrowed; dividend $0.28
Organon & Co.
2021-Q3 EPS reported
$4.52
revenue$4,701,000,000
- Revenue $1,600M, down 1% as-reported and 3% ex-FX YoY; net income from continuing ops $323M ($1.27 diluted EPS).
- Adjusted net income $424M ($1.67 diluted EPS); Adjusted EBITDA $636M (39.8% margin).
- Women's Health revenue $381M (-10% as-reported); Biosimilars +41%; Established Brands -6%.
- Board declares Q4 dividend $0.28/share, payable Dec 16, 2021, record Nov 22, 2021.
- Affirms FY guidance, narrows revenue range to $6.2B-$6.3B and Adj. EBITDA margin to 36.5%-37.5%.